Saint-Petersburg, Russia

Maxim Borovitov

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Proteologics, Inc.. Active years: 2012.

USPTO Granted Patents = 1 

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2012

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Maxim Borovitov: Innovator in Pyrimidine Derivatives

Introduction

Maxim Borovitov is a notable inventor based in St. Petersburg, Russia. He has made significant contributions to the field of medicinal chemistry, particularly through his work on pyrimidine derivatives. His innovative approach has the potential to impact the treatment of various viral infections and neurological disorders.

Latest Patents

Maxim holds a patent for "Pyrimidine derivatives as POSH and POSH-AP inhibitors." This patent describes how pyrimidine derivatives function as ubiquitination inhibitors, specifically targeting the ubiquitin ligase activity of POSH polypeptides. The implications of this work are profound, as these inhibitors could be useful in developing therapies for challenging medical conditions.

Career Highlights

Maxim is currently associated with Proteologics, Inc., where he continues to advance his research and development efforts. His work has garnered attention in the scientific community, showcasing his commitment to innovation in the pharmaceutical sector.

Collaborations

Maxim has collaborated with esteemed colleagues, including Nurit Livnah and Itzchak Angel. These partnerships have enriched his research and contributed to the advancement of their shared goals in the field of medicinal chemistry.

Conclusion

Maxim Borovitov's contributions to the development of pyrimidine derivatives highlight his role as an influential inventor in the medical field. His work not only showcases his innovative spirit but also holds promise for future therapeutic advancements.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…